ANI Pharmaceuticals ANIP Total Cost of Revenue
Total Cost of Revenue at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by ANI Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization.
The official record: ANI Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about ANI Pharmaceuticals's total cost of revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ANI Pharmaceuticals's total cost of revenue?
- ANI Pharmaceuticals (ANIP) reported total cost of revenue of $93.58M in Q1 2026.
- How has ANI Pharmaceuticals's total cost of revenue changed year-over-year?
- ANI Pharmaceuticals's total cost of revenue increased by 28.1% year-over-year, from $73.04M to $93.58M.
- What is the long-term trend for ANI Pharmaceuticals's total cost of revenue?
- Over 4 years (2021 to 2025), ANI Pharmaceuticals's total cost of revenue has grown at a 35.7% compound annual growth rate (CAGR), from $100.61M to $341.31M.
- What does total cost of revenue mean?
- The aggregate of all direct costs attributable to producing goods and delivering services that generated the company's revenue, including materials, labor, and overhead.